Detailed information about our clinical trials is provided through independent registries such as and EUdraCT.

Trial Description: Safety, feasibility and pharmacokinetic study to confirm that the recommended safe dose and schedule of ModraDoc006/r (oral docetaxel with ritonavir) as determined in a previous Phase I study is also safe and feasible in the target population of patients with metastatic castration-resistant prostate cancer
Phase: II
Status: Active, recruiting
Disease: Metastatic castration-resistant prostate cancer
Information: NCT03136640
Trial Description: Study to evaluate the effect of food on the pharmacokinetics of ModraDoc006 in combination with ritonavir, in an open-label, cross-over design. Patients will be randomized into two treatment groups receiving ModraDoc006/r week 1 under fasting and week 2 under fed condition, or vice versa
Phase: I
Status: Active, recruiting
Disease: Solid tumors
Information: NCT03147378



Modra Pharmaceuticals Announces Start of Phase II Study for its Lead Oral Chemotherapy in Patients with Metastatic Prostate Cancer
Read more

the IV to Oral switch

improving patient lives
Learn more


No current events
Read more